Listed

Larimar Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2019

Filed with the SEC on May 9, 2019 and accepted by EDGAR at May 9, 2019, 17:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-01-01 to 2019-03-31$0us-gaap:Revenues
Research and development3 months2019-01-01 to 2019-03-31$9.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-01-01 to 2019-03-31−$13.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2019-01-01 to 2019-03-31$500.0kus-gaap:InterestExpense
Net income3 months2019-01-01 to 2019-03-31−$13.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-01-01 to 2019-03-31−$0.35us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2019-01-01 to 2019-03-31−$12.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-01-01 to 2019-03-31$2.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-03-31$36.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-03-31$107.5mus-gaap:AssetsCurrent
Total assetsAt period end2019-03-31$110.2mus-gaap:Assets
Current liabilitiesAt period end2019-03-31$13.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-03-31$27.8mus-gaap:Liabilities
Long-term debtAt period end2019-03-31$20.0mus-gaap:LongTermDebt
Shareholders' equityAt period end2019-03-31$82.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-19-018086. Last ingested by Listed: Nov 13, 2026, 17:49 ET. Listed shows no prices and gives no investment advice.